ArticleJournal of neuro-oncology2026
Role of tumor momentum in neurocognitive deficits among pediatric brainstem glioma prior to treatment: a pilot study.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo investigate the association between tumor momentum indices and pretreatment neurocognitive function in children with brainstem gliomas (BSGs), and to evaluate their prognostic value for overall survival (OS).
methodsThis prospective pilot study enrolled 34 treatment-naïve children with histopathologically confirmed BSGs and 30 age-matched healthy controls at Beijing Tiantan Hospital, Capital Medical University. Neurocognitive function was assessed using the Wechsler Intelligence Scale for Children-Fourth Edition (WISC-IV), and emotional-behavioral performance was screened with the Child Behavior Checklist (CBCL). Tumor momentum was characterized by the MRS-derived Cho/Cr ("image momentum") and the Ki-67 proliferative index ("pathological momentum"). Kaplan-Meier analysis was performed to evaluate OS.
resultsPatients scored significantly lower than controls across all WISC-IV composite scores and subtests (p < 0.001). The Cho/Cr ratio was inversely correlated with verbal comprehension (ρ = -0.412, p = 0.015) and independently predicted potential verbal function deficit (OR = 4.281, 95% CI 1.146-15.994, p = 0.031). The Ki-67 index was positively associated with CBCL attention problems in high- versus low-Ki-67 subgroups (p = 0.036). Ki-67 was significantly associated with OS (p = 0.027), whereas neither Cho/Cr nor baseline cognitive status demonstrated prognostic value.
conclusionOur study provides the first direct evidence that treatment-naïve children with BSGs harbor significant neurocognitive impairment assessed by a standardized intelligence scale. The Cho/Cr ratio and the Ki-67 index capture complementary dimensions of tumor biology: the former may serve as a non-invasive biomarker for cognitive risk stratification, while the latter retains its established prognostic value for survival.
Indexed as
Identifiers
42189299What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.